C
CRISPR Therapeutics
Gene-based medicines for patients with serious diseases
At a glance
- Founded
- 2013
- Headquarters
- Switzerland
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning CRISPR Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later14 investors entered at this stage
- SOSR One
- CPClough Capital Partners
- GSGSK
- NPNew Leaf Venture Partners
Vertex Holdings
NEA- BSBristol-Myers Squibb
- CECelgene
Wellington Management- BIBayer Global Investments
- ABAbingworth
Franklin Templeton Investments
Vivo Capital- VPVertex Pharmaceuticals
Source: Dealroom Talent Intelligence.
Alumni founders
Former CRISPR Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
ZBZag BioEst. 2022
CTClade TherapeuticsEst. 2020
Chad CowanUnited States
VBVernal BiosciencesEst. 2021
Christian CobaughUnited States
ATAirNexis TherapeuticsEst. 2025
Maria FardisUnited StatesGlobal footprint
team presence
across markets
Patents
109 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about CRISPR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CRISPR Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.